Definitive Contract 75A50126C00005
Award Date 5/1/26
Potential Completion Date 10/31/28
Potential Value $7.5M
Awardee
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Minneapolis, MN 55410, USA
Solicitation Procedures
Basic Research
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- Isola Therapeutics Inc. has been awarded a $749,999 firm fixed-price definitive contract by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to conduct research and development for endobronchial lavage (EBL) as a preventative and therapeutic intervention for lung damage caused by pulmonary chemical agents. The contract, awarded on July 12, 2023, falls under the REDIRECT (Repurposing Drugs in Response to Chemical Threats) initiative, Area of Interest #15, and is being...
- This is a $37,506,620.00 definitive cost-sharing contract awarded by the U.S. Department of Health and Human Services (HHS), Office of the Assistant Secretary for Preparedness and Response (ASPR) to Invirsa, Inc. for the advanced research and development of INV-102, a medical countermeasure for the treatment of mustard gas keratopathy, under Broad Agency Announcement BAA-18-100-SOL-00003. The original solicitation sought proposals for the development of medical countermeasures against...
- Nuvox Pharma, L.L.C., a small disadvantaged business based in Tucson, Arizona, was awarded a $356,447.48 firm fixed-price definitive contract by the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the Department of Health and Human Services. The contract, awarded on July 28, 2023, extends previous research under Announcement of Opportunity #19 for the development of novel oxygen therapeutic nanoparticles (NANO2) for COVID-19 treatment. The contract has no...
- The Defense Health Agency awarded a $3.18M fixed-price level of effort contract to Inhalon Biopharma, Inc., a clinical-stage biopharmaceutical company based in Morrisville, North Carolina, for a Phase I placebo-controlled dose-escalation safety and pharmacokinetic study of IN-007, a nebulized pan-SARS ACE2-decoy therapeutic. This Small Business Innovation Research (SBIR) Program Phase III action supports pandemic preparedness initiatives by advancing an innovative inhaled treatment platform that...
- The U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response (ASPR), awarded a $481.7 million cost-plus-fixed-fee definitive contract to Shionogi Inc. on April 6, 2026, for late-stage development, FDA marketing authorization, procurement, and stockpiling of antibiotics to treat drug-resistant secondary bacterial infections and infections caused by biothreat pathogens. The contract, which extends through March 10, 2036, supports ASPR's...
- The Office of the Assistant Secretary for Preparedness and Response (ASPR) within the Department of Health and Human Services has awarded Synedgen, Inc., a Claremont, California-based small business, a $121.5 million definitive contract to advance development of PAAG17G (MIIST305), an orally administered, gut-restricted pharmaceutical product designed to reduce mortality and morbidity from acute ionizing radiation exposure, particularly gastrointestinal injury. The contract, awarded on September...
- This federal contract award was made by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services (HHS), to Inflammatix, Inc., a small disadvantaged business. The $749,999 firm fixed-price contract supports research and development for the Triverity cartridge, a diagnostic tool focused on infection severity and sepsis detection, under Area of Interest #2 of ASPR's Easy Broad Agency Announcement. The...
- The U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) awarded a $220,246,768 Definitive Contract to Aktivax, Inc. to support late-stage clinical development, regulatory approval, and procurement of 2-PAM autoinjectors as a drug-device combination product to treat organophosphate (OP) poisoning, including nerve agents, in adult and pediatric populations. This acquisition, which is not set-aside, will allow ASPR's Biomedical...
- Battelle Memorial Institute, a large nonprofit research and development organization headquartered in Columbus, Ohio, was awarded a delivery order valued at approximately $18.2 million by the Office of the Assistant Secretary for Preparedness and Response (ASPR) on September 29, 2025. The contract, which extends through August 30, 2030, supports the development and use of a human-relevant small animal model of sulfur mustard-induced inhalation injuries to screen potential medical...
- The U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) awarded a $98.6 million definitive contract to Osivax, a France-based company, on July 25, 2025, to conduct clinical proof-of-concept studies for OVX836, a single-shot broadly protective influenza A vaccine designed to provide immediate protection against emerging pandemic strains. This contract represents a cost-sharing arrangement with a completion date of July 24, 2028. The...